drugset / Trial / NCT06960577
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NaSingle-groupOpen-labelTreatment
Summary
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
Timeline
- Start
- 2025-05-15
- Primary completion
- 2028-08-30
- Completion
- 2028-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Vinblastine | Small molecule | — | — |